Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Endovasc, Basic Research Sign Letter Of Intent - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Endovasc, Basic Research Sign Letter Of Intent

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World


Endovasc, Ltd., Inc., Montgomery, TX, a biotechnology firm with two cardiovascular drugs approved for final FDA phase III trials, has signed a letter of intent with XM International, d.b.a. Basic Research Inc., Salt Lake City, UT, a nutraceutical company. According to the agreement, Basic Research will invest $2.5 million in developing, commercializing and marketing an array of nutraceutical products built on Endovasc’s current technology portfolio. In addition, Basic Research has agreed to pay Endovasc a 10% royalty on all revenues generated by these nutraceutical products.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters